Stockreport

CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

Celsion Corporation  (CLSN) 
Last celsion corporation earnings: 11/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.celsion.com/investor-relations
PDF  Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in [Read more]